THERE'S AN ALTERNATIVE TO WARFARIN
FOR PEOPLE WHO NEED ONE. IT'S CALLED WATCHMAN™.
A one-time procedure that effectively reduces the risk of stroke in patients with non-valvular atrial fibrillation.See How It Works
Explore our breakthrough products that make a meaningful difference in patient's lives.
Discover resources for Cardiovascular, Gastroenterology and Urology administrators.
Learn about living with an implanted device, explore health conditions and treatment options, and get support.
Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System
New Societal Guidelines Recommend Subcutaneous Implantable Cardioverter-Defibrillator for Patients with Ventricular Arrhythmias at Risk of Sudden Cardiac Death
Five-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy
Boston Scientific Announces Results For Third Quarter 2017
Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary
Boston Scientific Announces Agreement to Acquire Apama Medical
Boston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate™ Devices with the HeartLogic™ Heart Failure Diagnostic
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic
Real-World Data Confirms Long-Term Effectiveness Of Bronchial Thermoplasty
Boston Scientific Announces Results for Second Quarter 2017